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Abstract
Introduction: Rapid detection of, and optimized treatment for, severe sepsis and septic shock is crucial for
successful outcome. Heparin-binding protein (HBP), a potent inducer of increased vascular permeability, is a
potentially useful biomarker for predicting outcome in patients with severe infections. Our aim was to study the
systemic release and dynamics of HBP in the plasma of patients with severe sepsis and septic shock in the ICU.
Methods: A prospective study was conducted of two patient cohorts treated in the ICU at Karolinska University
Hospital Huddinge in Sweden. A total of 179 patients was included, of whom 151 had sepsis (126 with septic
shock and 25 patients with severe sepsis) and 28 a non-septic critical condition. Blood samples were collected at
five time points during six days after admission.
Results: HBP levels were significantly higher in the sepsis group as compared to the control group. At admission
to the ICU, a plasma HBP concentration of ≥15 ng/mL and/or a HBP (ng/mL)/white blood cell count (109/L) ratio
of >2 was found in 87.2% and 50.0% of critically ill patients with sepsis and non-septic illness, respectively. A
lactate level of >2.5 mmol/L was detected in 64.9% and 56.0% of the same patient groups. Both in the sepsis
group (n = 151) and in the whole group (n = 179), plasma HBP concentrations at admission and in the last
measured sample within the 144 hour study period were significantly higher among 28-day non-survivors as
compared to survivors and in the sepsis group, an elevated HBP-level at baseline was associated with an increased
case-fatality rate at 28 days.
Conclusions: Plasma HBP levels were significantly higher in patients with severe sepsis or septic shock compared
to patients with a non-septic illness in the ICU. HBP was associated with severity of disease and an elevated HBP at
admission was associated with an increased risk of death. HBP that rises over time may identify patients with a
deteriorating prognosis. Thus, repeated HBP measurement in the ICU may help monitor treatment and predict
outcome in patients with severe infections.
Introduction
Sepsis is defined as the systemic inflammatory response
to infection. In its more severe forms it causes tissue
hypoperfusion, hypoxia, lactic acidosis, and organ dys-
function [1,2]. Despite increasing awareness of the diag-
nosis, faster administration of antibiotics and
intravenous fluids, better technological support of organ
function and other recent advances in treatment, the
mortality rate in severe sepsis is approximately 35%
[3-6]. Most severe infections are due to bacteria [7] and
a large proportion (40%) of patients with severe sepsis
has lung dysfunction associated with cardiovascular
instability and deteriorating renal function [8]. Neutro-
phils have a pivotal role in the defense against bacterial
infections [9] and in sepsis, the extravasation of neutro-
phils and plasma to the focus of infection is an impor-
tant early step in the inflammatory process [10]
initiating events that evolve into a systemic inflamma-
tory response. Several inflammatory mediators, for
instance, IL-6, lactate, and lipopolysaccharide binding
protein (LBP), have been suggested as sensitive markers
of disease progression in septic shock [11,12] and can
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also help differentiate bacterial from non-bacterial con-
ditions [13].
Heparin-binding protein (HBP; also known as azuroci-
din and CAP37) is a multifunctional inflammatory med-
iator [14] with the ability to induce vascular leakage
[15]. The protein is contained within the secretory and
azurophilic granulae of human neutrophils [16] and is
secreted upon stimulation of the leukocytic membrane-
bound b2-integrins. HBP induces cytoskeletal rearrange-
ment of endothelial cells, which leads to breakdown of
cell barriers and an increase of the macromolecular
efflux [15]. It has been shown that HBP is released upon
neutrophil adhesion to endothelial cells, but also when
neutrophils are activated by circulating protein com-
plexes formed by streptococcal M protein and fibrino-
gen, a virulence mechanism which was shown to induce
severe organ damage in vivo [17,18]. HBP was recently
proposed as a biomarker for diagnosing bacterial menin-
gitis [19] and for the early detection of patients in the
emergency department (ED) at risk of developing severe
sepsis and septic shock [20].
Considering the high morbidity and mortality asso-
ciated with severe sepsis, a better risk-stratification of
patients in the ICU may assist clinicians to manage the
care of these patients more effectively and to improve
outcome. Repeated lactate measurements have pre-
viously been studied as a marker of mortality and out-
come [21]. Given the capacity of HBP to predict
vascular leakage in ED patients, it is also an interesting
candidate marker for monitoring patients with septic
shock in the ICU. In the present study, serial plasma
samples from critically ill patients treated in the ICU
were analyzed. The potential use of lactate and HBP in
diagnosing severe sepsis and septic shock, measuring





The present study consists of pooled results from two
studies, with identical inclusion criteria, of the regula-
tion of inflammatory markers in patients with severe
sepsis and septic shock conducted between 2003 and
2009. Patients were recruited at Karolinska University
Hospital Huddinge, a tertiary care hospital with 900
beds in Stockholm, Sweden. Study number one com-
prises 50 patients included between September 2003
and May 2005 [22]. Study number two has a total of
129 patients included between October 2005 and June
2009. The latter study also included a cohort of critically
ill, but initially non-infected patients. Patients were eval-
uated daily on weekdays from 8 am to 4 pm by a
trained research nurse and included on specified criteria
(see definitions). After retrospective review of complete
patient charts and laboratory and microbiological tests,
one control patient was reclassified as septic shock and
one as severe sepsis; two septic shock patients were
reclassified as severe sepsis, and one as control. Finally,
one patient was excluded from analysis altogether
because a clear classification proved impossible. Due to
hospital sub-specialization in Stockholm County, the
Karolinska University hospital in Huddinge does not
admit multi-trauma patients or those who have had
elective lower GI, thoracic or brain surgery.
Ethical issues
The studies were conducted in accordance with the
declaration of Helsinki and were approved by the Karo-
linska University ethics committee. Informed consent
was obtained from the patients or next of kin.
Definitions
Sepsis, severe sepsis, and septic shock were defined
according to previously described criteria [23]. The diag-
nosis of sepsis required a clinical assessment of infection
together with a systemic inflammatory reaction syn-
drome (SIRS). Severe sepsis was defined as sepsis in
addition to signs of acute reduction of organ perfusion
as previously described [24]. Septic shock was defined as
severe sepsis with hypotension requiring vasopressor
support or mean arterial pressure <70 mm Hg for ≥30
minutes despite adequate fluid resuscitation. Control
patients were defined as patients admitted for non-infec-
tious critical illness and with an expected length of stay
in the ICU longer than 24 hours.
Patient Characteristics
Individual clinical data were registered for the patients
(Table 1). Severity of disease was measured by the
Acute Physiology and Chronic Health Evaluation
(APACHE) II [25] at admittance and also by daily Sep-
sis-related Organ Failure Assessment (SOFA) scores
[26]. These and the final diagnoses were determined on
the basis of complete patient charts and laboratory tests.
The results of blood and other microbiological cultures
were recorded.
Blood and culture samples
Blood and plasma samples were collected in 5 mL tubes
at the time of inclusion or in the morning of the follow-
ing day (0 hour) and after 24, 48, 96 and 144 hours.
Ethylenediaminetetraacetic acid (EDTA) was used as the
anticoagulant in plasma samples. Tubes were immedi-
ately centrifuged at 3000 rpm for ten minutes and sepa-
rate aliquots of the plasma supernatants were stored at
-80ºC until analysis. Routine biochemical analyses were
performed. Two and three of the enrollment samples
were not available for HBP and lactate analysis, respec-
tively. Also, 25% of the samples from the 144-hour sam-
pling point and half that many from the 96-hour time
point were missing, mainly due to disrupted sampling
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after transfer of patients from the ICU to wards or other
hospitals. Thus, samples from the latter part of the per-
iod represent a group with a slightly different composi-
tion than at baseline. It lacks those who have died, but
also some who have improved.
Laboratory analysis
The concentration of HBP was determined by ELISA as
previously described [16]. Samples were coded and the
researcher performing the analyses was blinded to
patient data at the time. Briefly, microtiter plates
(NUNC) were coated with a mouse monoclonal anti-
body directed against human HBP (2F23A) [27]. Patient
plasma samples diluted 1/40 were added in duplicate.
Each plate also contained calibration samples of known
concentration of recombinant human HBP [28]. Plates
were incubated with a polyclonal rabbit antiserum
towards human HBP diluted 1/7000 [27]. The day-to-
day variation of the assay had a coefficient of variance
of <7%. Serum levels of IL-6 and IL-10 from the day of
inclusion were determined by Luminex cytokine multi-
plex analyses using a Singleplex bead kit (Invitrogen,
NY, USA) and the Luminex100 instrument (Luminex,
Austin, TX, USA). The minimum detectable level of IL-
6 was <3 pg/ml and for IL-10 <5 pg/ml. The samples
were analyzed in duplicate, using two different dilutions.
Standard laboratory analyses were performed at the clin-
ical chemistry laboratory, Karolinska University Hospital
in Huddinge, according to the manufacturer´s
instructions.
Statistical analysis
Chi-square tests, one-way analyses of variance and
Mann-Whitney U-tests were used to assess the distribu-
tions of covariates between the sepsis group and the
control group. Spearman´s non-parametric correlation
coefficient (rho) was used for calculating correlations
between HBP and other investigated parameters in the
patient groups. Cox proportional hazard models were
used to estimate hazard ratios (HR) of 28-days mortality
in sepsis patients according to initial and serial HBP-
values modeled as categorical variable (<15 ng/mL, >15
ng/mL). Separate models were fitted with base-line
values of HBP as predictor of death as well as base-line
and change in HBP (HBP modeled as a time-dependent
variable), adjusted for leukopenia (<4.0, >4.0), with s-
creatinine and s-bilirubin, treated as continuous vari-
ables. Effect modification by degree of sepsis severity
was assessed by examining the incidence rates of 28-day
mortality in different strata of HBP and by entering an
interaction term to the fully adjusted Cox models. Pro-
portionalities of hazards were assessed graphically and








Gender - n (%) male 67 (53.2) 15 (60.0) 19 (67.9) 0.18
28 day mortality - n (%) 26 (20.6) 8 (32.0) 11 (39.3) 0.08
Final diagnosis - n (%)
Lungs 30 (23.8) 13 (52.0)
Intra-abdominal 55 (43.7) 3 (12.0)
Urinary tract 17 (13.5) 4 (16.0)
Skin/soft tissue 12 (9.5) 1 (4.0)
Other septic conditions 12 (9.5) 4 (16.0)
Cardiac arrest and/or myocardial infarction 15 (53.6)
Liver transplantation (postop) and liver failure 6 (17.9)
GI-bleeding 2 (7.1)
Postoperative conditions 2 (7.1) NA
Other non-septic conditions 3 (14.3) NA
Comorbidities - n (%)
Malignancy 51 (41.1) 8 (34.8) 4 (14.3) 0.03
Diabetes mellitus 4 (3.2) 1 (4.4) 3 (10.7) 0.22
Cardiac disease 18 (14.3) 4 (16.0) 7 (25.0) 0.38
Liver disease 0 0 6 (21.4) <0.01
Other 43 (34.1) 9 (36.0) 6 (21.4) 0.40
Healthy 8 (6.4) 1 (4.0) 2 (7.1) 0.88
APACHE II score - mean 22.3 19.4 22.0 0.31
SOFA score - mean 10.5 8.3 9.3 0.01
APACHE, Acute Physiology and Chronic Health Evaluation; GI, gastrointestinal; n, number, SOFA, Sepsis-related Organ Failure Assessment.
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by testing for a non-zero slope in a generalized linear
regression of the scaled Schoenfeld residuals as a func-
tion of time.
The SPSS 14.0 software system (SPSS), GraphPad
Prism 5 (Graph Pad Software, La Jolla) and STATA/SE
(version 10.1 for Windows; StataCorp LP, College Sta-
tion, TX) were used for calculations.
Results
Characteristics of the patients
A total of 179 patients were included in the study.
Among these, 126 patients were diagnosed with septic
shock and 25 patients with severe sepsis without shock.
These 151 patients, with mainly abdominal and lower
respiratory tract infections, were analyzed as a group,
referred to as the sepsis group. The remaining 28
patients, referred to as the control group, were admitted
due to non-infectious conditions (mainly myocardial
infarction and cardiac arrest; see Table 1 for details).
In the sepsis group, only 6% were considered pre-
viously healthy. Blood cultures were obtained from 128/
151 patients, of which 64 (50.0%) were positive; all sep-
sis patients received antibiotics. The mean APACHE II
and SOFA scores at enrollment were 21.4 and 10.1,
respectively; 73.5% were treated with steroids and 93%
were treated with vasopressor drugs. Eighty percent had
been treated with vasopressors for more than 12 hours
before the first blood sample was taken.
In the control group, 14 patients (50.0%) developed an
infection sometime during the days following inclusion
and 24 patients (86%) were given antibiotics either as
treatment, or as part of a prophylaxis regimen. Twenty-
one control patients (75.0%) had shock at enrollment
and 28-day mortality was 39%. The mean APACHE II
score and SOFA score at enrollment was 22.1 and 9.3,
respectively, and vasopressors were used in 20 patients
(75.0%), as outlined in Table 1.
Plasma levels of HBP, lactate, CRP, and WBC at
enrollment
Enrollment samples were available for HBP and lactate
analysis in 149 and 148 sepsis patients, respectively. A
HBP concentration in plasma of ≥15 ng/mL was consid-
ered to be significantly elevated based on our previous
report of plasma HBP levels in patients with severe sep-
sis [20]. At enrollment, HBP levels were significantly
higher in both the septic shock group (P =.034) and in
the combined sepsis group (median 28, range 3 to 1.277
ng/mL) (P = .029) compared to the control group (med-
ian 14.5 to 614 ng/mL) (Figure 1A), although there was
no significant difference between the septic shock (med-
ian 30.3 to 1.277 ng/mL) and the severe sepsis group
(median 24.7 to 107 ng/mL) (P =.25). Lactate levels
were significantly elevated in the septic shock group
compared to the severe sepsis group (P =.030), but no
significant differences were found between the septic
shock (P =.090) and the sepsis group (P =.55) compared
to the control group (Figure 1B). C reactive protein
(CRP), IL-6 and IL-10 levels were significantly higher (P
<.01) but there was no significant difference in WBC
levels (P =.49) or SOFA scores (P =.28) (Figure 1C) in
the sepsis group compared to controls at enrollment.
HBP levels were significantly higher among patients
with positive blood cultures compared to those with
negative blood cultures (P <.01) (Figure 1D). Of the
patients with sepsis, 73.2% (109/149) had an HBP level
exceeding 15 ng/mL. For lactate; a level of >2.5 mmol/L,
found in 64.9% (96/148) of the sepsis patients, gave an
optimized sensitivity and specificity (Table 2). In the
control group, 14 patients (50.0%) had an elevated HBP
level (>15 ng/mL) at enrollment (Figure 1A). Seven of
these patients died. The 14 had been resuscitated after
cardiac arrest or had received massive blood transfu-
sions. Eight of them were subsequently diagnosed with
infections during their stay in the ICU. Among the con-
trols, lactate levels were elevated (>2.5 mmol/L) in 14
(56.0%) of the 25 available enrollment samples (Figure
1B).
In the whole study group (n = 179), both HBP and
lactate levels at enrollment were significantly higher
among 28 day non-survivors compared to survivors (P
<.05). There were correlations between HBP concentra-
tion at enrollment and WBC (rho =.31), lactate (rho
=.24), SOFA score (rho =.27), IL-6 (rho =.22), IL-8 (rho
=.19), D-dimer (rho =.38), activated partial thromboplas-
tin time (APTT) (rho =.25), creatinine (rho =.19) and
bilirubin (rho =.28). Lactate levels at enrollment corre-
lated to the same parameters and also to numbers of
ICU days (rho =.22), APACHE II score (rho =.25), INR
(rho =.29), ventilator days (n =.22) and platelet numbers
(rho =.27). CRP only correlated with creatinine (rho
=.25), IL-6 (rho =.31) and hospital days (rho =.19).
In patients with positive blood cultures, a total of nine
different Gram-positive, eight different Gram-negative
bacteria species, and one Candida species were found.
All species were found with an elevated HBP level,
except in one case of Enterobacter cloacae bacteremia.
No significant differences in HBP levels were found
between Gram positive and Gram negative bacteremia
(P =.93).
HBP/WBC ratio and sepsis-induced transient leukopenia
Some patients with severe sepsis develop a transient leu-
kopenia. Since HBP is released by neutrophils, the calcu-
lation of a HBP (ng/mL)/WBC (109/L) ratio in cases of
transient leukopenia was suggested in a previous study,
in which a ratio of >2 indicated an increased risk of
developing severe sepsis [20]. In the sepsis group, 26 of
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Figure 1 Plasma levels of HBP and lactate, SOFA score at enrollment in the ICU, correlation with HBP and blood culture results, and
HBP concentration and HBP/WBC ratio. Each dot represents the concentration in an individual plasma sample at enrollment of HBP (A) and
lactate (B). C shows SOFA scores at enrollment. D describes HBP concentration in patients in comparison with blood culture results. E-F shows
patients divided into non-leukopenic, leukopenic and controls describing HBP concentration (E), and HBP/WBC ratio (F). The patient groups are
described in the Methods section. Bars represent median values. The suggested cut-off value for HBP is marked at 15 ng/mL (A, D-E) and ratio
value 2 (F). Mann-Whitney´s non-parametric test was used for comparisons between the groups and P-values are given. Star symbols indicate
significant difference (P <.05). Open circles represent patients with transient leukopenia, open triangles represent patients with persistent
leukopenia, and open squares control patients with a positive blood culture. CRP, C-reactive protein; HBP, heparin-binding protein; SOFA, Sepsis-
related Organ Failure Assessment; WBC, white blood cells.
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149 (17.5%) patients had a transient leukopenia with an
initial WBC count of <4 (109/L), which was normalized
during the study period of 144 hours. All of these 26
patients had a ‘positive’ HBP/WBC ratio of >2 (Figure
1F). Despite the low WBC count, 15 (61.5%) of them
had an increased HBP level (≥15 ng/mL) (Figure 1E)
and another six patients had an elevated HBP level at
the second sampling after 24 hours. Six sepsis patients
had a persistent leukopenia (<2 × 109/L), due to che-
motherapy for hematological malignancies. These
patients had low HBP levels, but a HBP ratio >2 during
the whole study period (Figure 1 E-F).
In the control group, four patients had a WBC count
of <4 × 109/L at inclusion but also a HBP level of ≥15
ng/mL. In this group, calculation of the HBP/WBC ratio
did not increase the numbers of patients with a positive
HBP result (Figure 1E, F).
The combined use of HBP concentration and HBP/WBC
ratio
The combined use of an elevated HBP concentration
(≥15 ng/mL) and HBP ratio (>2) at enrollment identi-
fied 130 (87.2%) of the patients with sepsis. Of the 19
patients in the sepsis group who were HBP-negative
at enrollment, another eight patients had an increased
HBP level (≥15 ng/mL) in the 24 hour sample. Thus,
138 (92.6%) of the patients with severe sepsis/septic
shock had an elevated HBP level (concentration and/
or ratio) within 24 hours of enrollment in the ICU.
As a group, the remaining 11 HBP-negative patients
were somewhat less ill than the rest of the sepsis
cohort: four patients had an elevated lactate level
(>2.5 mmol/L), the mean SOFA score was 7 (com-
pared to 10.1 in the whole sepsis group) and the
mean APACHE II score was 19 (compared to 21.4)
and only one died.
Serial HBP measurements
Serial plasma concentrations were available for HBP,
lactate and CRP. The median plasma concentrations of
these three parameters (Figure 2 A, B) declined in the
sepsis group over time during the study period. The
median HBP levels were higher at each sampling time
point among non-survivors compared to those who sur-
vived and increased in the group of patients who died
within 28 days of enrollment (Figure 2C, D). In contrast,
lactate and CRP (Figure 2E, F) did not show an increas-
ing trend among non-survivors.
Comparing the last measured HBP and lactate con-
centrations between survivors and non-survivors,
revealed that both HBP and lactate levels were signifi-
cantly higher in 28 day non-survivors (P <.01).
HBP and 28-days mortality
A total of 34 patients died within 28 days among the
sepsis patients, 26 (20.6%) among those with septic
shock and 8 (32.0%) among those with severe sepsis,
corresponding to an overall case-fatality rate of 26.4%
(95% confidence interval (95% CI): 18.8 to 36.9) per 28
days. The 28-day case-fatality rate was increased four-
fold among sepsis patients with initial HBP >15 ng/mL,
estimated by Cox regression, adjusted for leukopenia, s-
bilirubin and s-creatinine levels (aHR:4.1 (95% CI:1.3 to
12.6)) (Figure 3). Although the stratified analyses were
based on small numbers, the results were largely consis-
tent in both sepsis groups and there was no evidence
for interaction (P =.18).
Controls that developed infection in the ICU
In the 14 control patients who developed clinical signs
of an infection during their stay in the ICU, eight had a
concomitant rise of HBP. One patient developed infec-
tion after transfer to another hospital and was only
Table 2 Laboratory measurements at enrollment
Characteristics Sepsis group
Number = 126 (%)
Severe sepsis
Number = 25 (%)
Control group
Number = 28 (%)
P-values
HBP ng/mL - n sampled 125 24 28
HBP ≥15 ng/mL 91 (72.8) 18 (75.0) 14 (50.0) <0.01
HBP/WBC ratio >2 78 (62.4) 8 (33.3) 12 (42.9)
HBP ≥15 ng/mL and/or HBP ratio >2 110 (88.0) 19 (79.2) 14 (50.0)
Lactate mmol/L n = 123 n = 25 n = 25 0.39
Lactate >4 47 (38.2) 7 (28.0) 8 (32.0)
Lactate 2.5- 3.9 39 (31.7) 6 (24.0) 6 (24.0)
Lactate 0-2.49 37 (30.1) 12 (48.0) 11 (44.0)
CRP ng/mL n = 126 n = 25 n = 26 <0.001
CRP >200 90 (71.4) 14 (56.0) 1 (3.9)
CRP 100 -199 22 (17.5) 5 (20.0) 2 (7.7)
CRP 0-99 14 (11.1) 6 (24.0) 23 (88.5)
CRP, C-reactive protein; HBP, heparin-binding protein; n, number.
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Figure 2 HBP and lactate concentration over time and 28 day survival. Results from consecutive samplings for HBP (A) and lactate (B) over
the study period. Plasma concentration for HBP (C-D) and lactate (E-F) in survivors and non-survivors after 28 days. SOFA score at enrollment in
survivors and non-survivors (G-H). Mann-Whitney´s non-parametric test was used for comparisons between the groups and P -values are given.
Star symbols indicate a significant difference (P <.05). The suggested cut-off value for HBP is marked at 15 ng/mL. Median values are given. HBP,
heparin-binding protein; SOFA, Sepsis-related Organ Failure Assessment.
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sampled once, thus precluding evaluation of changes in
HBP. Five patients developed clinical infection with no
corresponding rise of HBP. One of these had a Herpes
Zoster infection with little other signs of inflammation.
The remaining four were all admitted for cardiac arrest
that was later complicated by aspiration pneumonia,
fever and rising CRP. However, only one of the four was
hemodynamically unstable at the time that pneumonia
developed.
Discussion
This is the first study investigating plasma concentra-
tions of HBP in patients with severe sepsis and septic
shock in the ICU. We found that admission and serial
HBP measurements may be tools for predicting outcome
in patients with severe sepsis or septic shock. Elevated
HBP-levels at admission were associated with an
increased case-fatality rate at 28 days. Serial SOFA score
and lactate, which are established markers of outcome
in critically ill patients, and HBP, were all significantly
higher among 28-day non-survivors compared to survi-
vors at enrollment and 24 hours, but of these three,
only HBP was significantly elevated in non-survivors
compared to survivors at 144 hours.
In all, we found elevated HBP levels in 87% of the sep-
tic patients at study enrollment, using a cut-off of 15
ng/mL and/or a HBP/WBC ratio of >2. This result is in
line with a previous study in the emergency department,
which suggested that plasma HBP is an early marker for
severe sepsis and circulatory failure [20]. However, the
studied cohorts differ in many ways: in contrast to the
previous study on ED patients, samples in the present
study were collected in the ICU, at a later time point in
the course of disease and 80% of the patients were
already on treatment with vasopressors, due to circula-
tory failure, at the time of first sampling. Many patients
Figure 3 Kaplan-Meier survival estimates of 28-days mortality according to HBP-level >15 ng/mL or <15 ng/mL at inclusion. HBP,
heparin-binding protein.
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had serious underlying diseases, such as malignancies
and chemotherapy-induced leukopenia. Also, the spec-
trum of infectious foci was different with a large propor-
tion of patients having abdominal and post-operative
infections.
Transient leukopenia, which was found in 17.6% of the
patients, is a relatively common feature of sepsis [29].
Neutrophils are considered to be the main source of
HBP and consequently, none of the patients with persis-
tent leukopenia due to hematological malignancies had
elevated HBP concentrations. Yet, 61.5% of the patients
with transient leukopenia had high HBP levels, indicat-
ing that white blood cells, although temporarily
decreased, are still present in the body and neutrophils
are activated. Possible explanations for the low WBC
seen in septic patients are: enhanced exocytosis, exhaus-
tion or arrest of maturation of bone marrow cells, tissue
secernation of neutrophils, or tethering to the endothe-
lium during septic episodes [30,31]. Unsurprisingly, use
of the HBP/WBC ratio increased sensitivity in diagnos-
ing patients with transient leukopenia.
A large proportion of patients in the control group
also presented with elevated HBP levels, which indicates
that HBP, like all inflammatory biomarkers, is an acute
phase reactant, not entirely specific for infections. It is
worth noting that even though 28-day mortality was
almost twice as high in controls, median HBP at inclu-
sion was only half that of the septic patients. One could
speculate that serious events such as cardiac arrest or
massive blood transfusions lead to neutrophil activation
and the subsequent release of HBP, but not to the same
extent as in serious infections. Also, most of the patients
with cardiac arrest developed early-onset pneumonia,
probably as a result of aspiration, and thus a likely neu-
trophil activation due to both inflammatory and infec-
tious insult. Although control patients were classified as
non-infected at enrollment, 50% subsequently developed
infections during the study period. Most of the controls
that developed infections had a concomitant rise in
HBP. Those that did not rise in HBP were, except for
one patient, hemodynamically stable.
A total of 17 different bacterial species were cultured
from blood with Escherichia coli and Streptococcus
pneumoniae the most common findings. All but one of
the bacterial species was found together with an elevated
HBP concentration. This, together with the finding that
HBP levels were significantly higher among patients
with positive blood cultures, supports previous findings
that most bacteria are capable of inducing HBP release
[19].
The present study has several strengths. It was pro-
spective with a relatively large sample size, involving a
broad range of clinical presentations and diagnoses. The
diagnoses and bacterial culture findings are in line with
previous ICU studies and reflect a spectrum of patients
that are likely to be encountered if HBP was used as a
test in critically ill ICU patients. Inclusion criteria for
infected patients were identical in the two patient
cohorts and repeated blood samples were collected dur-
ing the first six days after enrollment in a large majority
of the study group.
Limitations of the study involve the control group,
which was small in size and composition, thus restrict-
ing generalizability. An unexpected difficulty was that,
even though the planned number of controls to
include was much lower than septic patients, their
recruitment took longer, despite wide inclusion cri-
teria. A significant problem, when recruiting ostensibly
non-infected ICU control patients, is that many will
develop infections, as was the case in our study. This
makes evaluation of HBP-levels difficult - are levels
increased due to non-infectious causes or to an incipi-
ent infection? Due to these circumstances, we have
restrained inferences from control patients to the day
of study inclusion, at which time we believe they were
truly non-infected or incipient infections were of
minor relevance. Finally, the study was single center
and we lack an extended comparison with some bio-
markers, notably procalcitonin.
Conclusions
In conclusion, this study on critically ill patients with
severe sepsis/septic shock shows: that plasma HBP levels
were significantly higher in patients with severe sepsis
or septic shock compared to patients with non-septic ill-
ness in the ICU; that HBP was associated with severity
of disease; that elevated HBP at admission was asso-
ciated with an increased risk of death; and that HBP
that rises over time may identify patients with a dete-
riorating prognosis. Previous findings on HBP as a sensi-
tive marker for severe sepsis were confirmed in a
different setting, underlining its potential as a valuable
diagnostic tool.
Key messages
• Plasma levels of the neutrophil-derived heparin-
binding protein (HBP) were significantly higher
among patients with severe sepsis and septic shock
as compared to non-infected critically ill ICU
patients.
• At admission to the ICU, an elevated HBP level
was found in 87.2% out of 151 septic patients.
• An elevated initial HBP level was associated with
an increased case-fatality rate at 28 days in septic
patients.
• HBP, lactate levels and SOFA scores were all sig-
nificantly higher at enrollment and 24 hours among
28-day non-survivors compared to survivors, but
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only HBP levels were significantly higher at 144
hours.
• The results indicate that admission and serial HBP
measurements may be additional tools for predicting
outcome in patients with severe infections.
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